SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

CDKI-73

Item No. 41099

CAS Registry No.:	1421693-22-2
Formal Name:	3-[[5-fluoro-4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]-benzenesulfonamide
Synonym:	Asnuciclib
MF:	$C_{15}H_{15}FN_6O_2S_2$
FW:	394.4
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CDKI-73 is supplied as a solid. A stock solution may be made by dissolving the CDKI-73 in the solvent of choice, which should be purged with an inert gas. CDKI-73 is sparingly soluble (1-10 mg/ml) in DMSO.

Description

CDKI-73 is an inhibitor of Cdk9/cyclin T1, Cdk1/cyclin B, and Cdk2/cyclin A complexes (K_is = 4, 4, and 3 nM, respectively).[1] It is selective for these complexes over the Cdk7/cyclin H complex (K_i = 91 nM). CDKI-73 is cytotoxic to HCT116 colorectal cancer cells (GI_{50} = <10 nM). CDKI-73 (0.25 or 1 µM) induces apoptosis in COLO 205, HCT116, HT-29, and KM12 colorectal cancer cells.[2] It reduces the levels of Bcl-2, cyclin D1, and myeloid cell leukemia-1 (Mcl-1), as well as decreases the mitochondrial membrane potential, in HCT116 cells when used at a concentration of 0.25 µM. *In vivo*, CDKI-73 (100 mg/kg every three days) decreases tumor volume in an HCT116 mouse xenograft model to a greater extent than the DNA-crosslinking agent cisplatin (Item No. 13119).

References

1. Shao, H., Shi, S., Huang, S., *et al.* Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: Synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities. *J. Med. Chem.* **56(3),** 640-659 (2013).
2. Rahaman, M.H., Lam, F., Zhong, L., *et al.* Targeting CDK9 for treatment of colorectal cancer. *Mol. Oncol.* **13(10),** 2178-2193 (2019).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM